Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours

Int J Oncol. 2006 Dec;29(6):1567-71.


It is generally accepted that T regulatory cells (T(reg) CD4(+)CD25(+)Foxp3(+)) play an important role in the suppression of tumour immunity. We examined the impact of T(reg) cell depletion with anti-CD25 antibody as adjuvant therapy in the treatment of minimal residual disease after excision of murine HPV16-associated tumours. We found that the depletion of T(reg) cells inhibited growth of the recurrences after surgery of HPV16-associated MHC class I+ as well as MHC class I-deficient tumours transplanted in syngeneic mice. These results demonstrate that depletion of CD25(+)CD4(+) T(reg) cells can be used as an efficient adjuvant treatment improving the results of surgery in the experimental systems mimicking human MHC class I+ and MHC class I-deficient, HPV16-associated neoplasms. Therefore, this therapeutic modality is worth being examined in patients with minimal residual HPV16-associated tumour disease after surgery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Combined Modality Therapy
  • Genes, MHC Class I / genetics
  • Genes, MHC Class I / immunology
  • Human papillomavirus 16 / isolation & purification*
  • Immunotherapy / methods*
  • Interleukin-2 Receptor alpha Subunit / immunology
  • Lung Neoplasms / immunology*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Lung Neoplasms / virology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm, Residual
  • Papillomavirus Infections / complications
  • Papillomavirus Infections / immunology*
  • Papillomavirus Infections / virology
  • T-Lymphocytes, Regulatory / immunology*


  • Interleukin-2 Receptor alpha Subunit